A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.
A first-of-its-kind therapy that can delay the onset of type 1 diabetes for up to 3 years is to be made available on the NHS.
The treatment uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them.
Women with type 1 diabetes who are pregnant or planning a pregnancy should be offered a pregnancy-specific 'artificial pancreas' device. That is the recommendation in draft guidance published today by NICE.
Hear from Leslie, a heart failure patient, his wife and carer Anne, and his consultant Dr Andrew Flett and discover how a NICE-recommended sensor the size of a paperclip is transforming heart failure care. Evidence from 3 randomised controlled trials shows it reduces hospitalisations by 34%.
This World Sickle Cell Day we’re sharing Jimi Olaghere’s story. Jimi was one of the first people in the world to receive CRISPR gene therapy. Jimi’s story show’s why our recommendation for this treatment on the NHS is so important.
Learn how our evidence-based guidance helped a London NHS trust standardise procurement and generate operational efficiencies.
Learn how NICE's healthtech guidance is accelerating NHS adoption of a simple bowel cancer test, preventing 140,000 unnecessary urgent referrals a year while keeping cancer detection rates stable.
